Friedreich's Ataxia Clinical Trial
Official title:
Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.
The focus of this study is to assess cardiac dysfunction in individuals with FRDA using 4 modalities: hand crank exercise, cardiac magnetic resonance (CMR) imaging, echocardiography (ECHO), and serum measurements of cardiac status, including high sensitivity troponin, a measure of cardiac myocyte damage; N-terminal prohormone of brain natriuretic peptide (NTproBNP), a measure of heart failure; and creatine phosphokinase (CPK), a general measure of muscle damage. While there have been individual studies of some of these modalities, there are no studies that correlate these parameters and it is not known which parameters are more sensitive to cardiac dysfunction. This preliminary study will help define the parameters most useful in assessing the cardiac involvement in FRDA. In addition, the study will investigate noninvasive tests and procedures that may serve as biomarkers for the neurologic disease. In other neurological diseases, non-invasive examination of the number and structure of nerve cells in the cornea has been assessed as an indication of disease progression. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02660112 -
(+) Epicatechin to Treat Friedreich's Ataxia
|
Phase 2 | |
Recruiting |
NCT02497534 -
Biomarkers in Friedreich's Ataxia
|
||
Completed |
NCT04102501 -
A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT01962363 -
EPI-743 in Friedreich's Ataxia Point Mutations
|
Phase 2 | |
Completed |
NCT02179333 -
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
|
||
Completed |
NCT01016366 -
Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia
|
Phase 2 | |
Recruiting |
NCT02069509 -
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
|
||
Terminated |
NCT00803868 -
Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
|
Phase 2/Phase 3 | |
Completed |
NCT02797080 -
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT02415127 -
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT00897221 -
A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT02840669 -
A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)
|
N/A | |
Completed |
NCT00697073 -
Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
|
Phase 3 | |
Completed |
NCT00631202 -
Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT01728064 -
Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT02593773 -
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
|
Phase 3 | |
Completed |
NCT01035671 -
Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT00811681 -
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept
|
Phase 3 | |
Completed |
NCT00537680 -
Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT02445794 -
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
|
Phase 1/Phase 2 |